Countries implementing this study were selected based on background disease burden of DR-TB and represent a diverse participant population, DR-TB patterns, and laboratory capacities. Clinical research sites (CRS) within countries were selected to ensure sufficient numbers of DR-TB cases to meet recruitment targets. Participants will be enrolled in nine clinical research sites. These are located in South Africa, Nigeria and Ethiopia
1. Ethiopia (Ethiopian Public Health Institute [EPHI])
• Borumeda Hospital, Amhara, Ethiopia and
• Dilchora Hospital, Diredawa, Ethiopia.
• Alert Hospital, Addis Ababa
• St. Peter Hospital, Addis Ababa
• Geda Health Center, Adama Hospital, Adama
2. Nigeria (Institute of Human Virology Nigeria LTDGTE [IHVN])
• Jos University Teaching Hospital (JUTH), Plateau state
• Plateau State Human Virology Research Centre (PLASVIREC), Jos Plateau state
• University of Abuja Teaching Hospital (UATH), FCT
• St. Gerald's Hospital, Kaduna state
• National Tuberculosis Leprosy Control Programme Saye, (NTBLCP) Kaduna state
• Aminu Kano Teaching Hospital (AKTH), Kano state
• Infectious Disease Hospital (IDH), Kano state
• Evangelical Reformed Church of Christ (ERCC), Alushi, Nasarrawa state
• Nigerian Institute of Medical Research, (NIMR) Yaba, Lagos state
• Mainland Hospital, Lagos
3. South Africa (Centre for the AIDS Programme of Research in South Africa
• Springfield Research Site, King DinuZulu Hospital (KDH) Complex Durban
4. South Africa (WITS Health Consortium)
• Jose Pearson TB Hospital, Bethelsdorp, Port Elizabeth